So in this video we are going to be talking about the top seven penny stocks that will be spiking in November 2019. Now the reason that I could say this concretely and confidently is because the companies on this list they literally tell you the exact dates at which price action changing events are going to be happening. They give this to us to given us their public FDA approval dates, their phase trial data releases, as well as dropping many hints and clues such as with insider activity presentations and institutional ownership. Now, along with these pics, I'm also going to be presenting some of my own best practices and strategies to get you started.

but you need to do your own due diligence in order to have a good time trading these stocks. Simply put, these are not stocks to just buy and dabble in. Most if not all of these companies are complete trash with a packet, a knack for seducing investors and running up their share price. Here at Zip Trader, we've had a long history of pointing out FDA approvals.

But look at some of the countless plays, what do you see in common? Well, they overreact to a news event and then they get beat down. You need to have a plan when trading these talks. That means having a concrete entry and a concrete exit point. But anyway, folks, you know that a lot of work goes into researching and putting these videos together.

In fact, the Top Penny Stocks videos take about four times as long as the other ones because I have to put a lot of work into the fundamental research and the technical research. and in return, the only thing that I really ask is that you hit that ravishing like button. And also if you see value, makes sure to subscribe for more short sweet simplified videos on how to trade the stock market. Ok so to start Quick Plug we officially released Zip Trader You a few days ago.

This is our structured course to help expedite the process of growing your account and becoming a self-sufficient trade of gluten in the program. We also have a whole section on my process for researching and trading Biotech catalysts. If this is something that you think is valuable to you, we would love to work with you and I'll put the link in the description below. We are about halfway through our enrollment, but if you use coupon code first 400 you will receive a discount.

Feel free to instant message me or comment below. If you have any questions whatsoever, check it out, make sure that you like what we have to offer and then make a decision. Ok so the first stock is a DMP now ad and P will be having their FDA approval decision on October 31st 2019 for their drug for opioid overdose and we have just broken into an upper direction. But honestly folks who cares if it goes up or down, we don't care, just need price action to trade off of.

And essentially how the FDA process works is we have many different stages in the approval process where the drug can fail. He goes through many different stages and opportunities to fail and then correct itself. So when we finally get to the final stage, its odds of failing drop dramatically because it's already worked out a lot of the kinks. But they still do film.

They still fail. At the end of the day, the FDA final stage approval for drugs is 80% Now, this doesn't mean that 80% of drugs end up getting approved. It means that 80% of drugs that go to the last stage in the process, the FDA approval stage end up ultimately getting approved. Now, what does that really mean? Well, it means that statistically speaking, based on prior years, 80% of drugs that do make it through to the last process do you ultimately get approved? Since these small cap companies are nearly completely reliant on certain drug approvals to make a profit, they usually have one or two drug approvals in their pipeline, so the whole company is basing their revenue guidance on one or two drugs.

So if they get failed and they get stonewalled all of a sudden, the stock has nowhere to go. But if they do well, all of a sudden investors are like whoa, they're going up. They're going to be the next best thing sets fried rice. So an FDA decision in one direction or the other will cause huge price action changes.

And really, it's a win-win for traders regardless of what happens. Because if it does get approved, we'll have a huge upward overreaction and if it gets disapproved, we will have a huge downward overreaction. The only exception to this is if we have a pre anticipatory reaction. But that's a whole nother topic.

But when it comes to FDA approvals, we don't just blindly bet on whether it's going to be approved or not. You're not in the business of guessing what the government is going to do. we rather use the information and statistics available to us to stack our probabilities in our favor. Combining our knowledge of the approval rate, we can then form a plan for how to trade it.

The first opportunity that we have is the anticipatory run-up. When an FDA decision is nearing, investors start banking on approvals, and if they are positively speculating, the price action is going to have a pre announcement run-up. And that means we can profit off the price action even before the announcement itself actually comes out. But you need to have a plan.

That means, for example, if we want to trade off anticipatory run-ups, we are looking for price strength in price Direction Intraday We talked a ton about elevating and deprecating factors. You're stacking odds of probabilities in your favor, and if we were looking to trade the actual announcement itself, we're still looking for elevating and deprecating factors. Sure, the percentage rate Of approval means that hey, it's more likely to get approved than not approved on average, right? But we're stacking it with a ton of other elevating factors because if you just bet on one elevating factor, 20% of the time they're going to be wrong and 20% of the time they're going to blow up your account. Sure, you could say I'm going to cut loss as quickly, but a lot of the time what happens is the shoot-down so quickly that it's very difficult to cut your losses quickly and it's very difficult to time your exit points sometimes with these penny stocks.

That being said, what are the monkeys saying? Well, our analysts slash monkey friends are giving it a price target at 350. That's a huge amount of upside from the current trading price at 70 cents. But let me be crystal clear, we do not care much for monkey opinions. We only care about them as far as they inspire sheep investors to pour in an FDA approval decision can drum up enough media attention that leads to sheep investors looking at price targets and then deciding to buy in our gold.

Knowing this is to simply slaughter the sheep and then feast on their bones. Their glorious bones. And this is why Zip Trader is not a vegetarian brand. In fact, if you do want to slaughter some sheep this month, make sure to comment below hashtag sheep Slaughter But looking more into a DMP We do have one big deprecating factor.

If we pull up the insider activity, we should ask ourselves, why is it that we've had 39,000 300 shares sold and not a single share purchased by the insiders? Could it be that the insiders are bearish on their own company? Again, the total cash volume is actually quite small. Its small because the actual share price itself is small, so if you multiply that by 39,000 it's not that many sales. But at the end of the day, the point is still constant. Why are there more insider selling? Why are there no insiders buying? And we actually dive very deep into insider activity and how to use that to predict price in our structured zip trader, you course.

But at a basic level it's not hard to understand that inside are selling and no insider buying is a huge deprecating factor for any company. so this is something to consider with a DMP as we wait for some running up and price action opportunities. What I'd be looking for with AD and P though is periods of heightened volume that could lead to further price appreciation. Okay, next so LPC and we'll be having their food for decision on November 11th for their drug for men with low testosterone low tea boys.

They've received several CR ELLs over the last year's two years, which you can think of as sort of like an FDA enforced delay on the process and this company has been widely anticipating this approval ever since and rightly so. This is a company that is in dire need of good news. They have every year since 2015, eaten away in all of their assets in order to stay afloat and bring new drugs through the pipeline. You could see it period after period after period after period with this balance sheet.

And this is why I Encourage folks to always look up the balance sheets for the stocks that they're researching because because there's so much that you can gauge from actually digging into a company. A lot of traders are like, wait, who cares how the company's doing I'm a trader I don't care how it's doing fundamentally. But the truth is, we could see just how reliant a company is on a certain drug. And if you can see that, you could say okay, well, how much is it going to spike if something good happens, how much is it going to decrease if something bad happens? However, the folks over at LPC and our smart cookies.

They're smart cookies folks. They've been able to continuously drive investor interest again and again and again, leading to an overall upper direction. And why is this significant? Well, because quite frankly most low cap stocks are in a solid downward direction. If you've looked at a chart of a hundred different penny stocks, odds are 95 to 99 of them are going to be any downward direction.

long term, but this one, well, it's in an upward direction and that really stands out. But some things to note: LP CN is in a low volume territory and it's on the lower end in terms of float. That means it's not smart to trade it until we get periods of higher volume. But the good news is that FDA announcements drive media attention and thus drive investors in, which in turn increases the volume and gives us price action trade-off of.

It's really a beautiful process folks, and another thing that I'd like to look for is spike ability. Do we have spike ability? If we are looking to take advantage of a future drug catalyst, Doesn't it make sense to look to see how this particular stock reacted to previous drug catalysts? This is checking for previous patterns and looking back over the last year we see two periods of massive fluctuation and using my special sophisticated, intelligent fundamental scanning tool also known as Google searching I could see exactly what happened on these dates. You can look up the date of the move and then the ticker and boom we have information. Wonderful folks! Welcome to 2019 And on January 17th we had positive results from an early study and that made the price action run up massively, had some anticipatory running up, and then boom, a run up and break down.

Every reaction in the stock market isn't over and it makes sense that it would break down after we've already covered this. But what? What happened on this state you may ask? Well back to the powers of research and on Google and we can see that during this period we had yet another positive release which then sparked this run-up So what? What do we know now? Well, LP CN has a history of spiking on positive news and moving forward. What is it that we have coming up? Well, An FDA Approval. The mother of good news, the mother of all positive news when it comes to drugs, and again, the new Spikes hero.

Because investors were excited about the prospect of eventually getting to that FDA approval so that their drugs can reach the market. The FDA approval itself is the main goal, but when it comes to price action, we need some height and volume and price ranked confirmation and ideally better direction before it makes sense for us to take a position. And this just comes back to our elevating and deprecating factors and also the trade ability. because if there's no float, there's no volume.

How are you gonna trade that? We need liquidity folks. liquidity. Ok, next are DHL Now our DHL has a history of Spike ability. It's trading at fair value and we will have an FDA approval decision on November Second, So how important is this FDA decision for the company? Well, it's not hard to figure out.

In fact, they tell us they spell it out for us if we go back to their earnings. Call from May 7th. their CEO explained that the infection that this drug treats affects 35 percent of the US population and 50 percent worldwide. Obviously this is from the founder and the CEO of the company, so it's going to be extra optimistic, but we don't care.

The thing that we care about is that the company has huge talking points in order to convince investors that this is a market that needs to be served and is quite lucrative if it is indeed breached and assuming approval. if it falls into the 80% approval rate, their drug has the potential and I quote to become the first-line standard of care therapy for this bacterial infection. This is the line that sheep investors eat up. Hope this is like putting Twinkies in the face of a 300-pound eight-year-old kid.

Sure, it may be ethically dubious to speculate on what's going to happen. Look folks, the kid is going to eat the Twinkies either way. so why not make money off it? By the way, if you are worried about following along and keeping up to date with these plays, get yourself in a good trading group. We have Zip Trader Circle which is our free Facebook group with over 18,000 traders in it and we post completely free nightly watch lists.

I'll put the link in the description below as well. Ok, next eight Qst will have their FDA approval decision on November 30th for their drug. I'm not going to lie to you as is currently I Just don't like this play. This has that traditional downward direction that we mentioned earlier, but literally no history of spike ability or reactiveness except these negative earnings releases here and here.

And there's not much reactiveness there. but I Always recommend folks trade like a spoiled brat and that means not taking a position unless the setup is as favorable as possible. But the reason that I mention this even though I don't love it is because it does have an FDA approval, which is again the mother of approvals. It is a month out from that date, so it's possible that things are going to change as we get closer and the FDA approval drums up some more interest and media attention.

Monkeys are giving it an average price target at 1550, which again, this is why we call them monkeys, folks. but at least we have a general upward bias in a Qst moving forward when it comes to sheep investors, but they aren't yet acting with their wallets as the price action continues to be beat down like a rabid dog. So I'd say before, really considering this, we are going to need to see signs of an uptrend. Remember folks, the goal of trading is to stack as many elevating factors as you can and remove as many deprecating factors as possible.

We don't take a position unless the price action convinces us. It convinces us to do it, folks. You stay on the sidelines that you're convinced to take a position, Then you take a position. Ok, next so we're going to be talking a bit about a little bit different of an opportunity.

In a world of sketchy penny stocks and crazy opportunities, O PLN is one of the craziest. We have so much spike ability that it would put a porcupine to shame. On October 22nd, they had announced that they had completed their first patient treatments and reiterated that they are the only Fda approved. They are the only ones that are approved for this pill that live gas and this is the only company that's approved for it.

And they are the only ones that hold the patent for it. And this is a line that investors eat up and as they result this otherwise pathetic price action. Random, Massively. so.

Why do we care? Well, Because their earnings are coming out on November 1st and so this is an opportunity for them to pump up their share price with optimistic statements that both drive in sheep investors but also drive more media attention to their new products. But moreover, it is an opportunity for the company to show investors just how profitable this weight loss solution is and for them to explain expected revenue guidance for the future. Previous spiked ability upon earnings and news tell us that this is going to be a win-win regardless of how well they do. But at the end of the day, o BLM is in threat of being delisted by the Nasdaq if it drops below $1 and hey, look, it's heading there.

So what this means in effect is they have every incentive to pump up their share price to make sure that they're not in threat of being delisted. So AlN A will be having to face data presentations after each other the first on November 8th and the second on the 9th and this is a cookie-cutter exposure. Play folks! presentations give companies the ability to explain what is going on, how their trials are going, and most importantly, create media attention, which again drives sheer volume. And if a stock has an upward sentiment, increased chair volume causes increased appreciation.

This is intuitive if a stock has overall upward sentiment and more investors find out about it, and they also adopt that sentiment. All of a sudden, the volume is pushing the share price up and this is exactly what we've seen. If you look at the price action, you can see very clearly they're running up and breaking into an upper direction over our red directional. SMA Why We love love love this folks.

Because they have been so good at driving investor sentiment that they've broken their long term downward direction and are now showing signs of reversing. We love buying sick dogs that show signs of reverse and we never just buy sick dogs off the side of the street. The real question with this though is whether or not they will be able to sustain this trend. A lot of the times they can't sustain the trend.

It's sort of a fake out, but the monkeys are projecting target prices at 294 percent to Upside at $21 which again, it begs the question of why I even bother posting these analysts price targets. But again, we like Emilie's price targets because they give us an idea of the overall sentiment. and since we know that tons of sheep investors look at it, this gives us opportunity and elevated factors to play off of. But again, if you're a sheep investor and you look at this price target as they buy signal, there's something wrong with you and number seven.

Now Mnk will be presenting phase data on Xi and quite frankly all I'm looking for is some serious price action. We have some previous patterns of getting tons of days where we have just these little intraday movements that aren't insane, but have five to ten percent of upside to trade off of combining this with more volume given the presentation on Xi and all of a sudden, we have a lot more fluctuations. One of the things that we love about these clean fluctuations is they allow you to simply buy in at conformation and then write the price action up and over and sell out at validation. Now Mirim is an eighth pick.

Think of this as a bonus pick to watch because at the end of the day, it just doesn't have the setup that I like and it just doesn't show the volume or the float that we could trade off of. They've been a sly puppy. They've had a fun pattern of just randomly running up for no apparent reason, mostly due to the sporadic nature of this low float stock. but there is some other speculation in that and this volume.

It's god-awful I Wouldn't touch this unless we see a massive increase in volume. but again, if they're able to drum up investor interest which you could say is unlikely with this, but it's possible, right? if they're able to do that, then this is going to be something that's worth watching and to get on your watchlist ahead of time, Don't hold me to this one. I Just wanted to present the opportunity so that you can see it so that I'm doing my part to pretty much show you everything that I see is valuable. Okay, anyways, folks, I Do hope that this video is helpful at the end of the day.

You are going to need to have concrete strategies and concrete plans in order to take advantage of these stocks. My suggestion is to spend some time doing your own due diligence into all the facts that I presented on this video and I'm looking to more things. Look at all the insider activity, Look at all of the balance sheets, look at the SEC filings, Look at a bunch of these different things. We have tons of free videos on the channel.

they can assist you with that just look it up, zip trader and then a topic that you need to learn about. And we have a free Zipped rhetorical Facebook group which can also assist you. and you could ask other traders what they think. And of course if you need more help in connecting the dots and using these picks to grow your account, we also have our structured zip trader you course and walkthrough roadmap to grow in your account.

and again links to all these things are in the description below. Anyways, I Hope you enjoyed this video. Make sure if you haven't already to hit that ravishing like button and subscribe for more short, sweet and simplified videos on how to trade the stock market. Have a great day and I'll see you in the next video.